Recursion Pharmaceuticals is a clinical-stage biotech company that industrializes drug discovery using technological innovation across life sciences. Their flagship drug, REC-994, is in the second phase of clinical trials that targets cerebral cavernous malformation. Apart from REC-994, the company has preclinical-stage products to treat Clostridium difficile colitis, ovarian cancer, and other cancers.